35 related articles for article (PubMed ID: 34991432)
1. Relationship between Primary Tumor Resection for Metastatic Small Intestine Neuroendocrine Tumors and Survival: A Propensity Score-Matched Analysis.
Yan H; Yin L; Han H; Jin Y; Liu Z
J Invest Surg; 2022 Jun; 35(6):1239-1247. PubMed ID: 34991432
[TBL] [Abstract][Full Text] [Related]
2. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.
Tsilimigras DI; Hyer JM; Paredes AZ; Ejaz A; Cloyd JM; Beane JD; Dillhoff M; Tsung A; Pawlik TM
J Gastrointest Surg; 2021 Sep; 25(9):2368-2376. PubMed ID: 33403563
[TBL] [Abstract][Full Text] [Related]
3. Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data.
Liu Y; Wang Z; Lin Q; Cui R; Tang W; Li G; Wang Z
BMC Gastroenterol; 2023 Nov; 23(1):408. PubMed ID: 37993767
[TBL] [Abstract][Full Text] [Related]
4. Palliative primary tumor resection may not offer survival benefits for patients with unresectable metastatic colorectal neuroendocrine neoplasms, one multicenter retrospective cohort study.
Yu G; Liu S; Wang Z; Liu Q; Ren H; Hu W
BMC Surg; 2024 Mar; 24(1):85. PubMed ID: 38475759
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristic-assisted surgical benefit stratification for resection of primary tumor in patients with advanced primary malignant bone neoplasms: a population-based propensity score-matched analysis.
Tong Y; Jiang L; Cui Y; Pi Y; Gong Y; Zhao D
Front Oncol; 2023; 13():960502. PubMed ID: 37746283
[TBL] [Abstract][Full Text] [Related]
6. Primary tumor resection improves survival benefit of stage IVB cervical carcinoma: a new perspective.
He Y; Zhang Y; Hu S; Zhang B; Zhang Z; Yao Y; Wang X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11013-11023. PubMed ID: 37335336
[TBL] [Abstract][Full Text] [Related]
7. Comparable long-term survival outcomes of endoscopic therapy versus surgical therapy for T1-2N0M0 duodenal neuroendocrine tumors.
Liu Z; Gao J; Wang P; Yin F; Zeng C; Chen Y
Surg Endosc; 2023 Jul; 37(7):5444-5452. PubMed ID: 37036503
[TBL] [Abstract][Full Text] [Related]
8. Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas.
Russo A; DiPeri T; Dumitra T; Tseng J; Pletcher E; Justo M; Chen C; Nissen N; Amersi F; Gong J; Hendifar A; Gangi A
J Neuroendocrinol; 2024 May; ():e13399. PubMed ID: 38760997
[TBL] [Abstract][Full Text] [Related]
9. Observation Versus Resection for Small, Localized, and Nonfunctional Pancreatic Neuroendocrine Tumors: A Propensity Score Matching Study.
Zhu J; Fu C; Zhang Y; Zhou X; Xiao W; Li Y
Pancreas; 2022 Jan; 51(1):56-62. PubMed ID: 35195596
[TBL] [Abstract][Full Text] [Related]
10. Effects of endoscopic therapy and surgical resection on long-term survival outcomes in patients with duodenal gastrointestinal stromal tumors: a surveillance, epidemiology, and end result program analysis.
Yan H; Liu X; Yin L; Han H; Jin Y; Zhu X; Liu Z
Surg Endosc; 2022 Nov; 36(11):8030-8038. PubMed ID: 35437643
[TBL] [Abstract][Full Text] [Related]
11. Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer.
Liu CQ; Shen CK; Du YX; Li ZM; Shi X; Wang Y; Wei WJ
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38570918
[TBL] [Abstract][Full Text] [Related]
12. Upfront primary tumor resection versus upfront systemic therapy for metastatic colorectal cancer: a systematic review and meta-analysis.
Lo SJ; Huang SH; Lai IL; Chern YJ; Hsu YJ; Liao CK; Cheng CC; Tsai WS; Hsieh PS; You JF
Int J Colorectal Dis; 2023 Jul; 38(1):186. PubMed ID: 37405554
[TBL] [Abstract][Full Text] [Related]
13. Risk of metastasis and survival in patients undergoing different treatment strategies with T1 colonic neuroendocrine tumors.
Wu X; Peng C; Lin M; Li Z; Yang X; Liu J; Yang X; Zuo X
J Endocrinol Invest; 2024 Mar; 47(3):671-681. PubMed ID: 37653287
[TBL] [Abstract][Full Text] [Related]
14. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.
Chen Q; Li K; Rhodin KE; Bartholomew AJ; Lidsky ME; Wei Q; Cai J; Luo S; Zhao H
HPB (Oxford); 2024 Jan; 26(1):125-136. PubMed ID: 37806829
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of primary tumor resection versus chemotherapy in patients with asymptomatic unresectable metastatic colorectal cancer: a retrospective cohort study using the target trial emulation framework.
Wu CC; Su CC; Lee PT; Chen YH; Hsu CW; Su YC
Am J Cancer Res; 2024; 14(5):2172-2186. PubMed ID: 38859829
[TBL] [Abstract][Full Text] [Related]
16. The Real-Life Impact of Primary Tumor Resection of Synchronous Metastatic Colorectal Cancer-From a Clinical Oncologic Point of View.
Pécsi B; Mangel LC
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672540
[TBL] [Abstract][Full Text] [Related]
17. Does primary tumor resection contribute to overall survival in unresectable synchronous metastatic colorectal cancer?
Ergun Y; Bal O; Dogan M; Ucar G; Dirikoc M; Acikgoz Y; Bacaksiz F; Uncu D
J Res Med Sci; 2020; 25():14. PubMed ID: 32174986
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors:
Ann Surg Open; 2023 Jun; 4(2):e290. PubMed ID: 37601463
[TBL] [Abstract][Full Text] [Related]
19. The roles of tissue resident macrophages in health and cancer.
Cao M; Wang Z; Lan W; Xiang B; Liao W; Zhou J; Liu X; Wang Y; Zhang S; Lu S; Lang J; Zhao Y
Exp Hematol Oncol; 2024 Jan; 13(1):3. PubMed ID: 38229178
[TBL] [Abstract][Full Text] [Related]
20. Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update.
Pavlidis ET; Pavlidis TE
World J Clin Cases; 2022 Sep; 10(27):9573-9587. PubMed ID: 36186187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
